Gastric inhibitory polypeptide, also known as glucose-dependent insulinotropic polypeptide, is an inhibiting hormone of the secretin family of hormones. From Wikipedia
New Cleveland Clinic data show that treatment discontinuation and low maintenance doses limit semaglutide’s and tirzepatide’s real-world weight-loss benefits, prompting exploration of four-receptor agonists.
